Lisberg, Aaron

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.

Shaverdian, N., Lisberg, A. E., Bornazyan, K., Veruttipong, D., Goldman, J. W., Formenti, S. C., Garon, E. B., & Lee, P. (2017) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 1,091

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC

Lisberg, A., Cummings, A., Goldman, J. W., Bornazyan, K., Reese, N., Wang, T., Coluzzi, P., Ledezma, B., Mendenhall, M., Hunt, J., et al. (2018) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 580

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

Bardia, A., Krop, I. E., Kogawa, T., Juric, D., Tolcher, A. W., Hamilton, E. P., Mukohara, T., Lisberg, A., Shimizu, T., Spira, A. I., et al. (2024) · Journal of Clinical Oncology

Breast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

Cited by 188

Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study

Sands, J., Ahn, M.-J., Lisberg, A., Cho, B. C., Blumenschein, G., Shum, E., Pons Tostivint, E., Goto, Y., Yoh, K., Heist, R., et al. (2025) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 130

A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC

Ahn, M.-J., Lisberg, A., Goto, Y., Sands, J., Hong, M. H., Paz-Ares, L., Pons-Tostivint, E., Pérol, M., Felip, E., Sugawara, S., et al. (2025) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 66

Datopotamab deruxtecan in locally advanced/metastatic urothelial cancer: Preliminary results from the phase 1 TROPION-PanTumor01 study.

Lisberg, A., Drakaki, A., Meric-Bernstam, F., Alhalabi, O., Kojima, T., Kato, M., Spira, A. I., Salkeni, M. A., Heist, R., Gao, X., et al. (2024) · Journal of Clinical Oncology

Bladder and Urothelial Cancer TreatmentsLung Cancer Treatments and Mutations

Cited by 15

DB-1311/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated castrate-resistant prostate cancer (CRPC).

Parsonson, A. O., Gandhi, C., Henick, B. S., Schmidt, A. L., Ye, D., Amin, H., Wise-Draper, T. M., Courtney, K. D., Tam, L., Jiang, S., et al. (2025) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchProtein Degradation and Inhibitors

Cited by 9